Safety and IOP-Lowering Effects of WB007

NCT04149899 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Primary Open Angle
Ocular Hypertension

Interventions

DRUG: WB007 0.05%
DRUG: WB007 0.15%
DRUG: WB007 0.4%
DRUG: Timolol 0.5%

Sponsor

Bausch & Lomb Incorporated